Fig. 3From: Brain pharmacokinetics of mono- and bispecific amyloid-β antibodies in wild-type and Alzheimer’s disease mice measured by high cut-off microdialysisCoronal brain sections of three representative individuals per group euthanized at the end of the microdialysis experiment, i.e. 6 h or 24 h after the intravenous injection of [125I]I-mAb3D6, [125I]I-mAb3D6-scFv8D3 or 125IBack to article page